Neema Afejuku Adelaja, MD
Family Medicine · Clifton Park, NYNPI 1184854101
Payments from drug & device makers
Across 226 payments — averaging $28.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$868
- AstraZeneca$753
- Novo Nordisk$627
- GSK$446
- Boehringer Ingelheim$441
- Lilly USA, LLC$419
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,37699%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $868 |
| AstraZeneca | 8 | $753 |
| Novo Nordisk | 26 | $627 |
| GSK | 12 | $446 |
| Boehringer Ingelheim | 15 | $441 |
| Lilly USA, LLC | 14 | $419 |
| Idorsia Pharmaceuticals US Inc | 6 | $317 |
| Otsuka America Pharmaceutical, Inc. | 11 | $252 |
| Esperion Therapeutics, Inc. | 2 | $219 |
| Pfizer | 9 | $219 |
| Alkermes, Inc. | 2 | $217 |
| Bayer | 5 | $180 |
| Amgen | 9 | $159 |
| Astellas Pharma US Inc | 5 | $140 |
| Alnylam Pharmaceuticals Inc. | 1 | $125 |
| Merck | 7 | $113 |
| E.r. Squibb & Sons, L.L.C. | 1 | $109 |
| Eisai Inc. | 1 | $106 |
| Vifor Pharma, Inc. | 1 | $97 |
| Abbott | 3 | $70 |
| Dexcom, Inc. | 3 | $67 |
| Johnson & Johnson | 4 | $62 |
| Lundbeck LLC | 3 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Novartis | 3 | $47 |
| Amarin Pharma, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| UCB, Inc. | 1 | $33 |
| Radius Health, Inc. | 1 | $29 |
| Tactile Systems Technology Inc | 1 | $26 |
| Exact Sciences | 1 | $21 |
| Verona Pharma, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,442 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $152,225 |
| EliquisApixaban | 61 | $63,010 |
| MounjaroTirzepatide | 40 | $41,127 |
| TrulicityDulaglutide | 27 | $40,785 |
| JardianceEmpagliflozin | 23 | $29,657 |
| JanuviaSitagliptin Phosphate | 23 | $29,616 |
| MyrbetriqMirabegron | 17 | $16,048 |
| OxycontinOxycodone Hcl | 12 | $7,047 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $6,917 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 150 | $5,625 |
| SynthroidLevothyroxine Sodium | 53 | $5,380 |
| Lidocaine | 54 | $4,207 |
| Omeprazole | 274 | $4,030 |
| Escitalopram Oxalate | 65 | $3,718 |
| Levothyroxine Sodium | 233 | $3,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $627 | $152,22583 claims |
| Lilly USA, LLCMounjaro, Trulicity | $419 | $81,91267 claims |
| PfizerEliquis | $219 | $63,01061 claims |
| Boehringer IngelheimJardiance | $441 | $29,65723 claims |
| MerckJanuvia | $113 | $29,61623 claims |
| Astellas Pharma US IncMyrbetriq | $140 | $16,04817 claims |
| AbbVieSynthroid | $868 | $5,38053 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $3,493233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Clifton Park
- Matthew CunninghamClifton Park$189K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.